Drug intelligence / Profile preview

EG-HZ

Development stage: Phase 1
Lead developer: EyeGene
Modality: Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

EG-HZ is a non-live, recombinant subunit vaccine being developed by EyeGene for the prevention of herpes zoster (shingles) caused by the varicella-zoster virus (VZV). The vaccine formulation consists of a recombinant varicella-zoster virus glycoprotein E (VZVgE) antigen combined with EyeGene's proprietary CIA09 adjuvant system, which is designed to enhance the immune response. EG-HZ is intended to provide a safer and potentially more effective alternative to existing shingles vaccines by eliciting a robust immune response in older adults. A Phase 1 clinical trial has been completed in healthy adults aged 50 to 70 years, evaluating the safety, tolerability, and immunogenicity of the vaccine compared to the active control Shingrix.

Other names: EG-HZ vaccine

Targets

gE (VZV glycoprotein E)

Beyond the preview

Go deeper on EG-HZ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EG-HZ.